Literature DB >> 24496889

Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scales.

Daniël Kleinloog1, Frits Roozen, Willem De Winter, Jan Freijer, Joop Van Gerven.   

Abstract

The subjective effects of cannabis and its main psychoactive component Δ(9) -tetrahydrocannabinol (THC) have played an important part in determining the therapeutic potential of cannabinoid agonists and antagonists. The effects mainly consist of feeling high, changes in perception, feelings of relaxation and occasionally dysphoric reactions. These effects are captured by two of the most frequently used visual analogue scales (VASs) in clinical (pharmacologic) research to measure subjective effects: VAS Bond and Lader (alertness, calmness and mood) and VAS Bowdle (psychedelic effects). In this analysis, the effects of THC on these VASs were compared within a total of 217 subjects who participated in 10 different studies. Not surprisingly, the item feeling high was found to be the best predictor for the effect of THC. Three separate clusters that describe the spectrum of subjective effects of THC were identified using different statistical methods, consisting of VAS "time", "thoughts" and "high" ("perception"), VAS "drowsy", "muzzy", "mentally slow" and "dreamy" ("relaxation") and VAS "voices", "meaning" and "suspicious" ("dysphoria"). These results provide experimental evidence that THC can evoke different classes of effects. These distinct subjective clusters could represent effects on various systems in the brain, which can be used to further differentiate the involvement of endocannabinoid systems in health and disease.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  THC; VAS; profile; subjective; visual analogue scales

Mesh:

Substances:

Year:  2014        PMID: 24496889      PMCID: PMC6878449          DOI: 10.1002/mpr.1424

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  29 in total

1.  Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

Authors:  Daniël Kleinloog; Marieke Liem-Moolenaar; Gabriël Jacobs; Erica Klaassen; Marieke de Kam; Ron Hijman; Joop van Gerven
Journal:  J Psychopharmacol       Date:  2012-05-16       Impact factor: 4.153

2.  Evidence for involvement of the insula in the psychotropic effects of THC in humans: a double-blind, randomized pharmacological MRI study.

Authors:  Hendrika H van Hell; Matthijs G Bossong; Gerry Jager; Gert Kristo; Matthias J P van Osch; Fernando Zelaya; René S Kahn; Nick F Ramsey
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-14       Impact factor: 5.176

3.  Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

Authors:  Linda E Klumpers; Christine Roy; Geraldine Ferron; Sandrine Turpault; Franck Poitiers; Jean-Louis Pinquier; Johan G C van Hasselt; Lineke Zuurman; Frank A S Erwich; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 4.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Authors:  Mary E Lynch; Fiona Campbell
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 5.  Role of cannabinoids in the treatment of pain and (painful) spasticity.

Authors:  Matthias Karst; Sonja Wippermann; Jörg Ahrens
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

Review 6.  Role of cannabinoids in multiple sclerosis.

Authors:  John P Zajicek; Vicentiu I Apostu
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

7.  Psychosis reactivity to cannabis use in daily life: an experience sampling study.

Authors:  Cécile Henquet; Jim van Os; Rebecca Kuepper; Philippe Delespaul; Maurice Smits; Joost A Campo; Inez Myin-Germeys
Journal:  Br J Psychiatry       Date:  2010-06       Impact factor: 9.319

8.  Manipulating brain connectivity with δ⁹-tetrahydrocannabinol: a pharmacological resting state FMRI study.

Authors:  Linda E Klumpers; David M Cole; Najmeh Khalili-Mahani; Roelof P Soeter; Erik T Te Beek; Serge A R B Rombouts; Joop M A van Gerven
Journal:  Neuroimage       Date:  2012-08-01       Impact factor: 6.556

9.  Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.

Authors:  Linda E Klumpers; Marianne Fridberg; Marieke L de Kam; Paul B Little; Niels Ole Jensen; Hendrik D Kleinloog; Christian E Elling; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

10.  Effect of intrapulmonary tetrahydrocannabinol administration in humans.

Authors:  L Zuurman; C Roy; R C Schoemaker; A Hazekamp; J den Hartigh; J C M E Bender; R Verpoorte; J L Pinquier; A F Cohen; J M A van Gerven
Journal:  J Psychopharmacol       Date:  2008-05-30       Impact factor: 4.153

View more
  5 in total

1.  A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease.

Authors:  Orsolya Györfi; Helga Nagy; Magdolna Bokor; Oguz Kelemen; Szabolcs Kéri
Journal:  J Neural Transm (Vienna)       Date:  2016-10-07       Impact factor: 3.575

2.  Stability analysis of clustering of Norris' visual analogue scale: Applying the consensus clustering approach.

Authors:  Zheng Guan; X Gregory Chen; Justin Hay; Joop van Gerven; Jacobus Burggraaf; Marieke de Kam
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

3.  Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Authors:  Tabea Schoeler; Jason Ferris; Adam R Winstock
Journal:  Transl Psychiatry       Date:  2022-09-06       Impact factor: 7.989

4.  Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts: Protocol for a Longitudinal Study Using a New Internet-Based Methodology.

Authors:  Marc Grifell; Guillem Mir Fuster; Mireia Ventura Vilamala; Liliana Galindo Guarín; Xoán Carbón Mallol; Carl L Hart; Víctor Pérez Sola; Francesc Colom Victoriano
Journal:  JMIR Res Protoc       Date:  2021-07-02

5.  Explorative Placebo-Controlled Double-Blind Intervention Study with Low Doses of Inhaled Δ9-Tetrahydrocannabinol and Cannabidiol Reveals No Effect on Sweet Taste Intensity Perception and Liking in Humans.

Authors:  Suzanne E M de Bruijn; Cees de Graaf; Renger F Witkamp; Gerry Jager
Journal:  Cannabis Cannabinoid Res       Date:  2017-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.